Bristol Myers Squibb (BMY) Capital Expenditures (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Capital Expenditures data on file, last reported at $347.0 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $347.0 million, up 33.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 14.22% YoY), and the FY2025 annual result was $1.3 billion, up 5.05% from the prior year.
• Capital Expenditures fell to $347.0 million in Q1 2026 per BMY's latest filing, from $370.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $378.0 million in Q4 2024 and troughed at $247.0 million in Q3 2022.
• A 5-year average of $307.8 million and a median of $320.0 million in 2025 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 46.24% in 2022 and fell as far as 8.52% in 2022.
• A 5-year view of Capital Expenditures shows it stood at $346.0 million in 2022, then decreased by 4.62% to $330.0 million in 2023, then increased by 14.55% to $378.0 million in 2024, then declined by 2.12% to $370.0 million in 2025, then dropped by 6.22% to $347.0 million in 2026.
• Business Quant data shows BMY's Capital Expenditures at $347.0 million in Q1 2026, $370.0 million in Q4 2025, and $320.0 million in Q3 2025.